VYGR Stock Analysis: Buy, Sell, or Hold?
VYGR - Voyager Therapeutics, Inc. Common Stock
$3.62
-0.15 (-3.85%)
▼
5d:
-12.14%
30d:
-12.35%
90d:
+6.16%
WAIT
LOW Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Get Alerted When VYGR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: VYGR is down 12.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: VYGR is down 12.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: VYGR is currently trading at $3.62, which is considered oversold relative to its 30-day fair value range of $3.77 to $4.13.
Technical Outlook: Technically, VYGR is showing sideways momentum. The price is currently testing key support at $3.75. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $14.89 (+295.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VYGR is showing sideways momentum. The price is currently testing key support at $3.75. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $14.89 (+295.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.77 -
$4.13
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.9%)
- BULLISH: Trading 295.5% below Wall St target ($14.89)
- WARNING: Recommendation downgraded due to -12.1% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$3.77 -
$4.13
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.75
Resistance Level
$4.46
Current Trend
Sideways
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.43
Wall Street Target
$14.89
(+295.5%)
Revenue Growth (YoY)
-59.9%
Share & Embed Analysis
Last updated: May 18, 2026 12:00 PM ET
Data refreshes hourly during market hours. Next update: 1:00 PM
Data refreshes hourly during market hours. Next update: 1:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VYGR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Alfred Sandrock
SELL
11511 shares
2026-04-02
Alfred Sandrock
SELL
14197 shares
2026-02-24
Nathan D Jorgensen
SELL
4668 shares
2026-02-24
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 65 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 53 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 56 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
